Cluster Headache—Acute and Prophylactic Therapy

Avi Ashkenazi, MD; Todd Schwedt, MD


Headache. 2011;51(2):272-286. 

In This Article

Somatostatin and Octreotide

Sicuteri et al conducted a controlled study to examine the efficacy of intravenous somatostatin for acute CH attacks.[29] Seventy-two attacks, experienced by 8 men, were studied. Somatostatin infusion was superior to placebo, and comparable to intramuscular ergotamine, in relieving CH pain. Matharu et al evaluated the efficacy of octreotide, a somatostatin analog that can be given subcutaneously, for acute CH.[30] Octreotide 100 μg was significantly superior to placebo with regard to headache response rates (52% vs 36%).

An important advantage of these drugs is their lack of vasoconstrictive effect, making them a viable treatment option for patients who cannot use triptans because of vascular diseases.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.